Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics

10th November 2016 (Last Updated November 10th, 2016 18:30)

GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy programmes.

GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy programmes.

The former is a biotechnology company, whereas the latter is a clinical-stage biotechnology company and both are based in the US.

Chinese-based biopharmaceutical company Yisheng Biopharma has announced a collaboration with US-based non-profit organisation The Scripps Research Institute (TSRI), which is focused on research in biomedical sciences.

The collaboration will be aimed at testing a new generation of AIDS vaccine based on trimmers and self-assembling nano particles designed by TSRI’s scientists and a technology developed by Yisheng Biopharma.

"The collaboration is expected to result in the development of more effective and safe vaccines against HIV."

The collaboration is expected to result in the development of more effective and safe vaccines against HIV.

Spanish biopharmaceutical company Oryzon Genomics has raised €0.6m ($0.67m) through the private placement of 175,071 shares of its common stock.

Priced at €3.43 ($3.82) a share, the placement was subscribed to by US-based Alzheimer’s Drug Discovery Foundation.

German-based Axiogenesis biotechnology company has signed an agreement with UK-based contract research organisation Metrion Biosciences.

As part of the agreement, the former will share its recently developed iPS-derived cardiomyocytes and neurons with Metrion Biosciences, which will profile and validate them using its high-quality screening platforms.

The commercial cell products will also be used in Metrion’s optimised ion channel screening, cardiac safety and translational phenotypic assays.

The agreement is expected to result in the development of human iPSC-derived cardiomyocytes and neurons for translational drug discovery.